Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1927-1934

  Eastell, R ^a   Rogers, A ^a   Ni, X ^b   Krege, J H ^b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Alendronate; Bone turnover; PINP; Raloxifene

Indexed keywords

ALENDRONIC ACID; COLLAGEN; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; RALOXIFENE; UNCLASSIFIED DRUG;

ADULT; BONE TURNOVER; CLINICAL EVALUATION; CONFERENCE PAPER; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PREMENOPAUSE; PROCOLLAGEN; RALOXIFENE; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 79959996409     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1380-5     Document Type: Conference Paper

References (31)

1. Burr DB, Martin RB, Schaffler MB, Radin EL (1985) Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18:189-200 (Pubitemid 15112335)
2. Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302 (Pubitemid 34651948)
3. Weinstein RS (2000) True strength. J Bone Miner Res 15:621-625 (Pubitemid 30174015)
4. Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184
5. Eastell R, Hannon RA (2008) Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67:157-162 (Pubitemid 351543397)
6. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
7. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66 (Pubitemid 43106908)
8. Civitelli R, Armamento-Villareal R, Napoli N (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20:843-851
9. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947-954
10. Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30-S44 (Pubitemid 32039511)
11. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124-1133 (Pubitemid 28311780)
12. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018 (Pubitemid 43867702)
13. Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65-74
14. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647 (Pubitemid 27510100)
15. Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE (2004) Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 11:405-415 (Pubitemid 40362164)
16. Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R (2000) The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15:129-137 (Pubitemid 30026940)
17. Walsh JS, Henry YM, Fatayerji D, Eastell R (2009) Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study. Osteoporos Int 20:355-362
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645 (Pubitemid 29384151)
19. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351 (Pubitemid 38177616)
20. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)
21. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
22. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535 (Pubitemid 35247036)
23. Silverman BW (1986) Density estimation for statistics and data analysis. In: Monographs on statistics and applied probability. Chapman and Hall, London
24. Michalska D, Stepan JJ, Basson BR, Pavo I (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91:870-877 (Pubitemid 43357752)
25. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992 (Pubitemid 36121052)
26. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258 (Pubitemid 41094365)
27. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592 (Pubitemid 34615244)
28. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306 (Pubitemid 351439247)
29. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
30. Martin T, Gooi JH, Sims NA (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 19:73-88
31. Rogers A, Glover SJ, Eastell R (2009) A randomised, doubleblinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45:1044-1052